APTX News and Press, Aptinyx Inc. From 03/25/21

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q4 2020 Earnings Call Mar 24, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q4 2020 Earnings Call Transcript

Aptinyx Inc. (APTX) Q4 2020 Earnings Conference Call March 24, 2021 05:00 PM ET Company Participants Nick Smith - Vice President of Corporate Development & Investor Relations Norbert Riedel - Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Andy...

Aptinyx (APTX): Q4 GAAP EPS of -$0.20 beats by $0.04.Cash and cash equivalents were $141M.Press Release For further details see: Aptinyx EPS beats by $0.04

Phase 2 studies in fibromyalgia and painful DPN enrolling as planned – data readouts expected in 1H 2022 Phase 2 study in cognitive impairment expected to recommence imminently – data readout expected in 2H 2022 Reported data from Phase 2 exploratory stud...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences: Cowen 41...

Today, we revisit a small biotech concern called Aptinyx for the first time since July 2019. The stock has been range-bound since the stock imploded after a failed mid-stage trial early in 2019. The company does have several compounds in development for a variety of CNS disorders....

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10 th Annual SVB Leerink Gl...

NYX-2925 is currently under evaluation in two Phase 2b studies of chronic pain: one in patients with fibromyalgia and a second in patients with painful diabetic peripheral neuropathy Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transform...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virt...